TOday’s Movers: Blueprint Medicines (NASDAQ:BPMC) Stock Rating Maintained by Analysts at Jefferies; $88.0 Target Price Indicates 0.98 % Potential

April 17, 2018 - By Peter Erickson

Blueprint Medicines Corporation (NASDAQ:BPMC) Logo

Blueprint Medicines (NASDAQ:BPMC) Rating Reaffirmed

Jefferies now has a $88.0 target price per share on the $3.81B market cap company or 0.98 % upside potential. In analysts report sent to investors on Friday morning, Blueprint Medicines (NASDAQ:BPMC) shares have had their Buy Rating maintained by equity research analysts at Jefferies.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Coverage

Among 8 analysts covering Blueprint Medicines (NASDAQ:BPMC), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicines has $10900 highest and $78 lowest target. $94.63’s average target is 8.58% above currents $87.15 stock price. Blueprint Medicines had 11 analyst reports since October 23, 2017 according to SRatingsIntel. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) earned “Buy” rating by Jefferies on Friday, December 22. BTIG Research maintained the shares of BPMC in report on Tuesday, October 31 with “Buy” rating. As per Monday, April 16, the company rating was maintained by JMP Securities. As per Monday, November 13, the company rating was maintained by BTIG Research. Goldman Sachs upgraded the shares of BPMC in report on Monday, December 11 to “Buy” rating. The rating was maintained by Wedbush on Monday, November 6 with “Buy”. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Monday, April 16 by Wedbush. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) earned “Buy” rating by Canaccord Genuity on Wednesday, November 1. Canaccord Genuity maintained the shares of BPMC in report on Monday, April 16 with “Buy” rating. The rating was maintained by Morgan Stanley with “Overweight” on Monday, October 23.

The stock increased 0.79% or $0.69 during the last trading session, reaching $87.15. About 451,472 shares traded or 25.93% up from the average. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 101.73% since April 17, 2017 and is uptrending. It has outperformed by 90.18% the S&P500.

Analysts await Blueprint Medicines Corporation (NASDAQ:BPMC) to report earnings on May, 2. They expect $-1.09 EPS, down 29.76 % or $0.25 from last year’s $-0.84 per share. After $-1.23 actual EPS reported by Blueprint Medicines Corporation for the previous quarter, Wall Street now forecasts -11.38 % EPS growth.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. The company has market cap of $3.81 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It currently has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.